Clinical Trials Logo

Glucose Intolerance clinical trials

View clinical trials related to Glucose Intolerance.

Filter by:

NCT ID: NCT02742662 Completed - Obesity Clinical Trials

Smart Technology for Weight Loss and Metabolic Health

Start date: April 2016
Phase: N/A
Study type: Interventional

The study will evaluate whether a technology-based lifestyle intervention program using primarily a smartphone platform is an acceptable and effective way for treating obesity. The goal of the program is to achieve weight loss and enhance the health of overweight or obese subjects by improving their diet and activity via smartphone applications as compared with conventional in-person weight management programs.

NCT ID: NCT02726256 Not yet recruiting - Type 2 Diabetes Clinical Trials

G-CREDIT (Gangnam-Cohort for Risk Evaluation of Diabetes and Impaired Glucose Tolerance)

Start date: January 2007
Phase: N/A
Study type: Observational

The prevalence of type 2 diabetes has consistently increased and type 2 diabetes can cause many types of vascular complications. Diabetes develops due to glucose intolerance. Early detection and intervention in the stage of glucose intolerance makes it afford to prevent overt diabetes and its complications. This study was designed to make a cohort of korean patients with glucose intolerance to construct a long term database about clinical characteristics of these patients.

NCT ID: NCT02722902 Terminated - Glucose Intolerance Clinical Trials

Carnitine Infusion and Insulin Resistance

Start date: May 2016
Phase: N/A
Study type: Interventional

Insulin resistant subjects and type 2 diabetic patients are characterized by a decreased metabolic flexibility: a reduced capability to switch from fat oxidation in the basal state to carbohydrate oxidation in the insulin-stimulated state. This metabolic inflexibility is an early hallmark in the development of diabetes. Recent evidence suggests that a low carnitine availability may limit acetylcarnitine formation, thereby reducing metabolic flexibility. Thus, when substrate flux in the muscle is high, acetyl-CoA concentrations increase, leading to inhibition of pyruvate dehydrogenase (PDH) and thereby reducing glucose oxidation. The conversion of acetyl-CoA to acetylcarnitine relieves this acetyl-CoA pressure on PDH. To provide more direct insight into the effect of carnitine in preventing metabolic inflexibility and insulin resistance and to further explore the mechanism of action is the focus of this research. Here, we hypothesize that the capacity to form acetylcarnitine may rescue lipid-induced insulin resistance. To this end, insulin resistance will be induced by lipid infusion in healthy volunteers and it will be tested whether carnitine co-infusion can alleviate insulin resistance.

NCT ID: NCT02720393 Completed - Prediabetes Clinical Trials

Impact of No-carrageenan Diet on Glucose Tolerance in Prediabetes

Start date: February 2016
Phase: N/A
Study type: Interventional

Participants will be randomly assigned to either regular or no-carrageenan prepared diets to determine whether the no-carrageenan leads to improvement in glucose tolerance. Hemoglobin A1c is the primary outcome measure.

NCT ID: NCT02708966 Completed - Clinical trials for Impaired Glucose Tolerance

Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.

Start date: March 2016
Phase: Phase 2
Study type: Interventional

Prediabetes (PD) was defined as an state in which glucose levels are above normal but not enough to meet criteria for the diagnosis of type 2 diabetes (T2D). PD can be presented as impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and glycated hemoglobin A1c (A1C) altered. The International Diabetes Federation (IDF) reported that in 2013 the prevalence of IGT was 6.9% which is equivalent to approximately 316 million individuals with IGT, it is expected that by 2035 this number will increase to 417 million people affected. Many hypoglycemic effects attributed to Gymnema sylvestre have been reported, including: increase of insulin secretion, regeneration of pancreatic islet cells, increased glucose utilization in various ways and inhibition of glucose uptake in the intestine.

NCT ID: NCT02706821 Completed - Prediabetes Clinical Trials

Anti-diabetic Effects of Persimmon Leaf Extract

Start date: February 2014
Phase: N/A
Study type: Interventional

The investigators performed a 8-week, randomized, double-blind, placebo-controlled crossover human trial to evaluate the efficacy and safety of persimmon leaf extract on blood glucose. The investigators measures changes in diabetes associated parameters, including fasting blood glucose, postprandial blood glucose, insulin, C-peptide and HbA1c.

NCT ID: NCT02706093 Completed - Glucose Intolerance Clinical Trials

Metabolic Adaptations in Response to High Intensity Interval Training in Obese Adults

HT
Start date: May 3, 2016
Phase: N/A
Study type: Interventional

The overall objectives are to: 1. Assess mechanisms underlying HIIT-induced improvements in insulin resistance at the whole-body, tissue, and cellular levels. 2. Systematically compare different HIIT regimens to help identify effective "doses" of HIIT that may be optimal for improving metabolic health in obese adults. 3. Assess the ability/willingness of obese subjects to adhere to a long-term HIIT program. Findings from these studies will greatly expand knowledge about the effects of HIIT on metabolic health, and will provide valuable information for development of programs aimed at maximizing key metabolic benefits of exercise.

NCT ID: NCT02702245 Completed - Glucose Intolerance Clinical Trials

Effects of Two Doses of Thylakoids on OGTT

Start date: January 2014
Phase: N/A
Study type: Interventional

This cross-over intervention study aims to investigate the effect of two doses of thylakoids to an oral glucose tolerance test (OGTT) on glucose and insulin homeostasis as well as appetite regulating hormones in healthy volunteers.

NCT ID: NCT02700334 Completed - Prediabetes Clinical Trials

Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes

Start date: October 2016
Phase: Phase 4
Study type: Interventional

Prediabetes is a term that refers to alterations in glucose homeostasis, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or both, involving a higher risk of progression type 2 diabetes mellitus (T2DM). Dapagliflozin is a selective and reversible inhibitor of sodium-glucose type 2 (SGLT-2) co-transporter, which reduces renal glucose reabsorption and promotes the glucose excretion through urine, so that the blood glucose is improved in patients with T2DM. Although this mechanism is independent of insulin, there are evidence of improved secretion and insulin sensitivity, so it is interesting to assess these effects in patients with prediabetes, as potential therapy for treating such disorders and prevent progression to T2DM. The aim of this study is to evaluate the effect of Dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. The investigators hypothesis is that the administration of dapagliflozin improve insulin secretion and insulin sensitivity in patients with prediabetes.

NCT ID: NCT02695433 Completed - Metabolic Syndrome Clinical Trials

Replacing Refined Carbohydrates With Healthy Fats on Cardio-metabolic Markers

AV2
Start date: March 1, 2016
Phase: N/A
Study type: Interventional

The primary goal is to to characterize the effects of consuming 1 avocado fruit 7 days / week (5-7 days is acceptable) compared to a no avocado relatively low fat, carbohydrate control treatment over a 12 week period on insulin sensitivity as measured by the Matsuda composite index of insulin sensitivity (MISI).